2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1334

Identification of Key Regulators for Resolution of Chronic Inflammatory Arthritis through a Systems Approach
Abstract Number: 1335

p62/SQSTM1 Modulates Bone Erosions in a Murine Model of Rheumatoid Arthritis
Abstract Number: 1336

Unique Role for miR429 in RA and Acute Model of Arthritis
Abstract Number: 1337

ASN002, a Novel Dual SYK/JAK Inhibitor, Demonstrates Strong Efficacy in a Rat Model of Collagen-Induced Arthritis
Abstract Number: 1338

Important Role of CD11c+ Dendtritic Cells in Inflammatory Arthritis
Abstract Number: 1339

Role of Hexokinase-2 in Synovial Lining Hypertrophy in Murine Arthritis
Abstract Number: 1340

Is Depression in Patients with Rheumatoid Arthritis Associated with Disease Activity? Comparative Study between Germany and Brazil
Abstract Number: 1341

The Impact of Anti-Cyclic Citrullinated Peptide Seropositivity on Erosion Prevalence Among Patients with RA of Varying Disease Duration
Abstract Number: 1342

Comprehensive Provider Judgment Outweighs Disease Activity Measures in the Decision to Not Escalate Therapy in Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 1343

Gingival Bleeding and Periodontitis in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Abstract Number: 1344

Impact of Fibromyalgic RA on Composite Scores; Results from a Longitudinal Study of RA Patients Initiating Bdmard Therapy
Abstract Number: 1345

Tender Joints Have Low Associations with Patient’s Evaluation of Joint Pain and Ultrasound Findings Explored at Joint Level in Patients with Rheumatoid Arthritis
Abstract Number: 1346

Selective Effect of Rituximab on IgG4 Anti-CCP Autoantibodies in Rheumatoid Arthritis Patients
Abstract Number: 1347

Ultrasonography and Synovial Histology in the RA Patients in Remission
Abstract Number: 1348

Swollen Joint Count, but Not Inflammatory Cytokines, Differs By Frequency of Fish Consumption in a Cross-Sectional Rheumatoid Arthritis Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].